Table 3. Use of Helixor in Cancer Treatment: Clinical Reports Describing Therapeutic Endpointsa
| Reference Citation(s) | Type of Study | Type(s) of Cancer | No. of Patients: Enrolled; Treated; Controlb | Strongest Benefit Reportedc | Concurrent Therapyd | Level of Evidence Scoree |
| [35] | Randomized trial | Breast, stages I–III | 692; 192; 274 | Improved survival | Yes | 1iiA |
| [36] | Randomized trial | Colorectal, metastatic | 60; 20; 20 | Improved mean survival | Yes | 1iiA |
| No. = number. | ||||||
| aSee text and the NCI Dictionary of Cancer Terms for additional information and definition of terms. | ||||||
| bNumber of patients treated plus number of patients controlled may not equal number of patients enrolled; number of patients enrolled = number of patients initially recruited/considered by the researchers who conducted a study; number of patients treated = number of enrolled patients who were administered the treatment being studied AND for whom results were reported; historical control subjects are not included in number of patients enrolled. | ||||||
| cStrongest evidence reported that the treatment under study has anticancer activity or otherwise improves the well-being of cancer patients. | ||||||
| dChemotherapy, radiation therapy, hormonal therapy, or cytokine therapy administered/allowed at the same time as mistletoe therapy. | ||||||
| eFor information about levels of evidence analysis and an explanation of the level of evidence scores, see Levels of Evidence for Human Studies of Cancer Complementary and Alternative Medicine. |
References
- Gutsch J, Berger H, Scholz G, et al.: [Prospective study in radically operated breast cancer with polychemotherapy, Helixor® and untreated controls]. Dtsch Z Onkol 21: 94-101, 1988.
- Douwes FR, Wolfrum DI, Migeod F: [Results of a prospective randomized study: chemotherapy versus chemotherapy plus "biological response modifier" in metastasizing colorectal carcinoma]. Dtsch Z Onkol 18 (6): 155-64, 1986.
